Brentuximab for refractory CD30+ Hodgkin's lymphoma: clinical and cost-effectiveness
CADTH
Record ID 32014000173
English
Authors' recommendations:
Six non-randomized studies were identified regarding the clinical effectiveness of brentuximab for patients with refractory CD30+ Hodgkins lymphoma. No economic evaluations were identified.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/may-2013/RB0582%20Brentuximab%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Hodgkin Disease
- Immunotoxins
- Antineoplastic Agents, Immunological
- Brentuximab Vedotin
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.